Press Releases | BioNTech

23 June 2023

Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine

Read on

2 June 2023

BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO

Read on

26 May 2023

Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission

Read on

25 May 2023

Changes in the Supervisory Board of BioNTech SE and Voting Results from the Annual General Meeting 2023

Read on

8 May 2023

BioNTech Announces First Quarter 2023 Financial Results and Corporate Update

Read on

24 April 2023

BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023

Read on

3 April 2023

BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

Read on

28 March 2023

BioNTech Announces New ADS Repurchase Program

Read on

27 March 2023

BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

Read on

20 March 2023

BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications

Read on

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BioNTech disavows any obligation to update the information contained in such press releases after the date of their issuance.